Uveitis-Pipeline Review, H1 2015

Uveitis-Pipeline Review, H1 2015

  • Products Id :- GMDHC6260IDB
  • |
  • Pages: 159
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Uveitis-Pipeline Review, H1 2015


Global Markets Direct's, 'Uveitis-Pipeline Review, H1 2015', provides an overview of the Uveitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Uveitis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Uveitis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Uveitis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Uveitis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Uveitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Uveitis Overview 11

Therapeutics Development 12

Pipeline Products for Uveitis-Overview 12

Pipeline Products for Uveitis-Comparative Analysis 13

Uveitis-Therapeutics under Development by Companies 14

Uveitis-Therapeutics under Investigation by Universities/Institutes 18

Uveitis-Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

Uveitis-Products under Development by Companies 22

Uveitis-Products under Investigation by Universities/Institutes 26

Uveitis-Companies Involved in Therapeutics Development 27

AbbVie Inc. 27

Aciont Inc. 28

Apitope International NV 29

BBB Therapeutics B.V. 30

Can-Fite BioPharma Ltd. 31

Clearside BioMedical, Inc. 32

Effimune SAS 33

Eleven Biotherapeutics Inc. 34

Endocyte, Inc. 35

Enzo Biochem, Inc. 36

EyeGate Pharmaceuticals, Inc. 37

ForSight VISION4, Inc. 38

HanAll Biopharma Co., Ltd. 39

Icon Bioscience, Inc. 40

IMMD Inc. 41

Johnson & Johnson 42

Neuroptis Biotech 43

Novartis AG 44

Ocata Therapeutics, Inc. 45

OncoNOx ApS 46

Panoptes Pharma Ges.m.b.H. 47

Pfizer Inc. 48

pSivida Corp. 49

Regeneron Pharmaceuticals, Inc. 50

Santen Pharmaceutical Co., Ltd. 51

SynDevRx, Inc. 52

TxCell SA 53

Virogenomics, Inc. 54

XOMA Corporation 55

Uveitis-Therapeutics Assessment 56

Assessment by Monotherapy Products 56

Assessment by Target 57

Assessment by Mechanism of Action 59

Assessment by Route of Administration 61

Assessment by Molecule Type 63

Drug Profiles 65

2B3-201-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

adalimumab-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

ATXUV-1-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

ATXUV-2-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

B27-PD-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

celecoxib-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

CF-101-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

Col-Treg-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

Cytectin-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

dexamethasone acetate-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

Dexamethasone Sodium Phosphate-Visulex-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

EBI-028-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

EC-1496-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

EC-1669-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

fluocinolone acetonide-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

FR-104-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

gevokizumab-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

HL-036-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

IBI-70090-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

IMD-0354-Drug Profile 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

INV-17-Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

LFG-316-Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

lodamin-Drug Profile 99

Product Description 99

Mechanism of Action 99

R&D Progress 99

NOP-3-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

NS-2-Drug Profile 101

Product Description 101

Mechanism of Action 101

R&D Progress 101

OX-1001-Drug Profile 102

Product Description 102

Mechanism of Action 102

R&D Progress 102

PA-2612-Drug Profile 103

Product Description 103

Mechanism of Action 103

R&D Progress 103

Peptides to Modulate TCR for Uveitis-Drug Profile 104

Product Description 104

Mechanism of Action 104

R&D Progress 104

plastoquinone decyl triphenylphosphonium bromide-Drug Profile 105

Product Description 105

Mechanism of Action 105

R&D Progress 105

PP-001-Drug Profile 107

Product Description 107

Mechanism of Action 107

R&D Progress 107

PPL-003-Drug Profile 108

Product Description 108

Mechanism of Action 108

R&D Progress 108

Recombinant Enzymes for Uveitis-Drug Profile 109

Product Description 109

Mechanism of Action 109

R&D Progress 109

sarilumab-Drug Profile 110

Product Description 110

Mechanism of Action 110

R&D Progress 110

sirolimus-Drug Profile 112

Product Description 112

Mechanism of Action 112

R&D Progress 112

Small Molecules to Inhibit Kinase for Uveitis and Inflammatory Bowel Disease-Drug Profile 114

Product Description 114

Mechanism of Action 114

R&D Progress 114

Stem Cell Therapy for Autoimmune Diseases-Drug Profile 115

Product Description 115

Mechanism of Action 115

R&D Progress 115

triamcinolone acetonide-Drug Profile 116

Product Description 116

Mechanism of Action 116

R&D Progress 116

V-404-Drug Profile 117

Product Description 117

Mechanism of Action 117

R&D Progress 117

Uveitis-Recent Pipeline Updates 118

Uveitis-Dormant Projects 147

Uveitis-Discontinued Products 150

Uveitis-Product Development Milestones 151

Featured News & Press Releases 151

Jan 05, 2015: Clearside Biomedical Initiates Phase 2 Clinical Trial For the Treatment of Macular Edema Associated With Non-Infectious Uveitis 151

Dec 18, 2014: Aldeyra Therapeutics Submits FDA IND Filing for Noninfectious Anterior Uveitis 151

Dec 17, 2014: TxCell Receives EU Orphan Drug Designation For Col-Treg In The Treatment Of Non-Infectious Uveitis 152

Dec 16, 2014: Aldeyra Therapeutics Abstract Accepted at 2015 American Academy of Allergy Asthma & Immunology Annual Meeting 153

Dec 16, 2014: Portage announces further successful validation of its new proprietory cell permeable peptide platform technology 153

Oct 28, 2014: TxCell achieves positive results for Col-Treg in a model of autoimmune uveitis 154

Oct 15, 2014: Clearside Biomedical Announces Ongoing Results in Phase 1/2 Clinical Trial in Patients with Non-infectious Uveitis 155

Oct 06, 2014: Portage Announces Additional Consultants To Expedite Its PPL-003 Development Programs 155

May 22, 2014: Col-Treg granted Advanced Therapy Medicinal Product classification by the European Medicines Agency 156

May 20, 2014: AbbVie Receives Orphan Drug Designation for HUMIRA from the U.S. Food and Drug Administration for the Investigational Treatment of Certain Forms of Non-infectious Uveitis 157

Appendix 158

Methodology 158

Coverage 158

Secondary Research 158

Primary Research 158

Expert Panel Validation 158

Contact Us 158

Disclaimer 159

List of Tables

Number of Products under Development for Uveitis, H1 2015 12

Number of Products under Development for Uveitis-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 15

Number of Products under Development by Companies, H1 2015 (Contd..1) 16

Number of Products under Development by Companies, H1 2015 (Contd..2) 17

Number of Products under Investigation by Universities/Institutes, H1 2015 18

Comparative Analysis by Late Stage Development, H1 2015 19

Comparative Analysis by Clinical Stage Development, H1 2015 20

Comparative Analysis by Early Stage Development, H1 2015 21

Products under Development by Companies, H1 2015 22

Products under Development by Companies, H1 2015 (Contd..1) 23

Products under Development by Companies, H1 2015 (Contd..2) 24

Products under Development by Companies, H1 2015 (Contd..3) 25

Products under Investigation by Universities/Institutes, H1 2015 26

Uveitis-Pipeline by AbbVie Inc., H1 2015 27

Uveitis-Pipeline by Aciont Inc., H1 2015 28

Uveitis-Pipeline by Apitope International NV, H1 2015 29

Uveitis-Pipeline by BBB Therapeutics B.V., H1 2015 30

Uveitis-Pipeline by Can-Fite BioPharma Ltd., H1 2015 31

Uveitis-Pipeline by Clearside BioMedical, Inc., H1 2015 32

Uveitis-Pipeline by Effimune SAS, H1 2015 33

Uveitis-Pipeline by Eleven Biotherapeutics Inc., H1 2015 34

Uveitis-Pipeline by Endocyte, Inc., H1 2015 35

Uveitis-Pipeline by Enzo Biochem, Inc., H1 2015 36

Uveitis-Pipeline by EyeGate Pharmaceuticals, Inc., H1 2015 37

Uveitis-Pipeline by ForSight VISION4, Inc., H1 2015 38

Uveitis-Pipeline by HanAll Biopharma Co., Ltd., H1 2015 39

Uveitis-Pipeline by Icon Bioscience, Inc., H1 2015 40

Uveitis-Pipeline by IMMD Inc., H1 2015 41

Uveitis-Pipeline by Johnson & Johnson, H1 2015 42

Uveitis-Pipeline by Neuroptis Biotech, H1 2015 43

Uveitis-Pipeline by Novartis AG, H1 2015 44

Uveitis-Pipeline by Ocata Therapeutics, Inc., H1 2015 45

Uveitis-Pipeline by OncoNOx ApS, H1 2015 46

Uveitis-Pipeline by Panoptes Pharma Ges.m.b.H., H1 2015 47

Uveitis-Pipeline by Pfizer Inc., H1 2015 48

Uveitis-Pipeline by pSivida Corp., H1 2015 49

Uveitis-Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 50

Uveitis-Pipeline by Santen Pharmaceutical Co., Ltd., H1 2015 51

Uveitis-Pipeline by SynDevRx, Inc., H1 2015 52

Uveitis-Pipeline by TxCell SA, H1 2015 53

Uveitis-Pipeline by Virogenomics, Inc., H1 2015 54

Uveitis-Pipeline by XOMA Corporation, H1 2015 55

Assessment by Monotherapy Products, H1 2015 56

Number of Products by Stage and Target, H1 2015 58

Number of Products by Stage and Mechanism of Action, H1 2015 60

Number of Products by Stage and Route of Administration, H1 2015 62

Number of Products by Stage and Molecule Type, H1 2015 64

Uveitis Therapeutics-Recent Pipeline Updates, H1 2015 118

Uveitis-Dormant Projects, H1 2015 147

Uveitis-Dormant Projects (Contd..1), H1 2015 148

Uveitis-Dormant Projects (Contd..2), H1 2015 149

Uveitis-Discontinued Products, H1 2015 150

List of Figures

Number of Products under Development for Uveitis, H1 2015 12

Number of Products under Development for Uveitis-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 14

Number of Products under Investigation by Universities/Institutes, H1 2015 18

Comparative Analysis by Clinical Stage Development, H1 2015 20

Comparative Analysis by Early Stage Products, H1 2015 21

Assessment by Monotherapy Products, H1 2015 56

Number of Products by Top 10 Targets, H1 2015 57

Number of Products by Stage and Top 10 Targets, H1 2015 57

Number of Products by Top 10 Mechanism of Actions, H1 2015 59

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 59

Number of Products by Top 10 Routes of Administration, H1 2015 61

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 62

Number of Products by Top 10 Molecule Types, H1 2015 63

Number of Products by Stage and Top 10 Molecule Types, H1 2015 64

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

AbbVie Inc.

Aciont Inc.

Apitope International NV

BBB Therapeutics B.V.

Can-Fite BioPharma Ltd.

Clearside BioMedical, Inc.

Effimune SAS

Eleven Biotherapeutics Inc.

Endocyte, Inc.

Enzo Biochem, Inc.

EyeGate Pharmaceuticals, Inc.

ForSight VISION4, Inc.

HanAll Biopharma Co., Ltd.

Icon Bioscience, Inc.


Johnson & Johnson

Neuroptis Biotech

Novartis AG

Ocata Therapeutics, Inc.

OncoNOx ApS

Panoptes Pharma Ges.m.b.H.

Pfizer Inc.

pSivida Corp.

Regeneron Pharmaceuticals, Inc.

Santen Pharmaceutical Co., Ltd.

SynDevRx, Inc.

TxCell SA

Virogenomics, Inc.

XOMA Corporation

Uveitis Therapeutic Products under Development, Key Players in Uveitis Therapeutics, Uveitis Pipeline Overview, Uveitis Pipeline, Uveitis Pipeline Assessment

select a license

Single User License
USD 2000 INR 136140
Site License
USD 4000 INR 272280
Corporate User License
USD 6000 INR 408420



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com